Bristol-Myers Squibb near settlement in Vanlev suit

Share this article:
Bristol-Myers Squibb (BMS) is close to settling a shareholder lawsuit over its failed experimental blood-pressure drug Vanlev for more than $150 million, The Wall Street Journal reported today. The settlement, which could be announced as early as this week, pertains to a suit that alleges Bristol-Myers Squibb hailed Vanlev as a potential blockbuster even as a dangerous side effect surfaced. The agreement could bring to nearly $1 billion the amount of money BMS has agreed to return to shareholders in the past two years. Vanlev was designed to treat high blood pressure and in the late 1990s was widely seen as the product that would restore BMS’ slumping drug portfolio. Some analysts predicted Vanlev could reach sales of as much as $4 billion a year. However, Vanlev never made it to market, with news of its trouble leading to sharp declines in BMS stock.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters